Search

Focuses on the possible role of African prostitutes in developing an HIV vaccine. Basis of the notion; Problems with other methods against AIDS; Mechanism of HIV virus.

Focuses on the efforts to develop a vaccine for the AIDS virus. Spending for vaccine development; Belief of researchers that a vaccine can be made; Problems with HIV; Lack of an ideal animal model; Existence of people who are resistant to the virus; Efforts of drug companies; Strict standards for vaccines. INSET: Not our job, by M.S..

The article reports on evidence which has emerged which suggests that Merck & Co.'s experimental HIV vaccine may have made its recipients more vulnerable to the deadly AIDS virus. The evidence has prompted researchers to warn participants in other trials that similarly made vaccines for a range of other diseases might also increase their susceptibility to HIV. The impact the evidence may have on further vaccine research is discussed.

The article reports on the result of a research conducted at the Ragon Institute, a joint project of Massachusetts General Hospital, the Massachusetts Institute of Technology (MIT) and Harvard University, which investigated the possibility that some HIV sectors or group pf amino acids can be targeted for AIDS vaccines or drugs.

This article reports on the move of AIDS scientists to question the results of a study that found the first vaccine against human immunodeficiency virus (HIV). Conducted by researchers from the U.S. Army and Thailand, the study concluded that the vaccine is effective in protecting people against HIV. AIDS scientists said a second analysis of the study showed the results may have been a fluke. Jerome Kim, a scientist with the U.S. Army, said they stand with the results.

The article reports on the failure of the experimental AIDS vaccine of Merck & Co. to prevent test subjects from becoming infected with HIV as well as offer indication that it might delay the onset of full-blown AIDS. Mark Feinberg of Merck has expressed disappointment over the failure of this trial which was considered the leading edge of research on T-cell based HIV vaccines.

Reports that independent scientists contested a suggestion by VaxGen Inc. that its experimental AIDS vaccine protected some people against HIV infection.

Discusses evidence that developing a preventative AIDS vaccine may be more difficult than previously thought, according to a study presented at the XIV International AIDS Conference. Case of an HIV-positive man whose immune system was suppressing the AIDS virus without drugs, until he became infected with a second strain by having unprotected sex; Mutability of the virus, which means that a vaccine might only work against one strain; Implications for vaccine development.

Highlights the presentation made by Merck & Co. on how its experimental AIDS vaccine acts in humans.

Reports on the plan of Merck & Co. to run a monkey trials of an experimental AIDS vaccine developed by researchers at the Institute of Human Virology at the Baltimore campus of the University of Maryland.

Discusses alliances between biotechnology firms and nonprofits in the United States and India, to produce inexpensive AIDS vaccines for developing countries. Efforts to avoid patent infringement in the developed world; Efforts by the International AIDS Vaccine Initiative (IAVI) to transfer technology of U.S. firm Therion Biologics Inc. to Indian vaccine maker Serum Institute of India Ltd.; Other potential partnerships.

Reports on the development of a possible vaccine for the AIDS virus. Development of the vaccine by Harvard University scientists; Tests of the vaccine on monkeys who did not become sick when infected with the virus; Details of how the vaccine works by priming the immune system to control the virus rather than repelling it; Concern as to the lasting effect of the vaccine.

Focuses on the clinical tests of human immunodeficiency virus (HIV) vaccines by several researchers designed to control the spread of acquired immunodeficiency syndrome (AIDS). Trial conducted by David Ho, an AIDS researcher; Account on the treatment approach to HIV by Bruce Walker, a researcher at Massachusetts General Hospital.

Reports that the National Institutes of Health signaled a new commitment to developing an AIDS vaccine by naming David Baltimore, to reinvigorate their foundering research program. Role of Baltimore; Reactions to the appointment of Baltimore; Baltimore's scientific achievements; Reason so few companies are working on an AIDS vaccine.